Ionis pharmaceuticals recently licensed-out its antisense drug to AstraZeneca in deal total worth up to USD 330 million
Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee. AstraZeneca will now be taking care of the development and commercialization of IONIS-AZ5-2.5Rx, designed to treat the kidney disease. Ionis will receive up to USD 300 million more in tiered royalties as well as development and regulatory milestones making it a USD 330 million deal in total.
Roche has signed a deal worth USD 1.9 billion to buy Flatiron
Pharma industry giant Roche has recently signed a de...
